People with extreme, life-threatening allergic reactions might do as well to use a nasal spray as to jab themselves in a ...

Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...

Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

The Health Canada authorization marks an important regulatory milestone in the NS002 development program. This clearance confirms the acceptability of the proposed trial design, supporting safety data ...

The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...

Neurelis, Inc., today announced it will present at the Alliance to Cure Cavernous Malformation (CCM) 21st International CCM Scientific & Clinical Meeting to be held November 6-7, 2025, in Atlanta, ...

Viatris Inc. VTRS delivered third-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which beat the Zacks Consensus ...

Viatris Inc. (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial ...

Direct-to-consumer drug sales aim to simplify pricing and increase transparency by allowing patients to buy directly from ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a patent filing and ...

Nabarun Dasgupta, a senior scientist at UNC-Chapel Hill and expert on fatal drug overdoses, was awarded a 2025 MacArthur Fellowship. The so-called “genius grant” comes with an $800,000 prize.